| Heading: |
Trastuzumab Deruxtecan |
| Question ID: |
1744291 |
| UIN: |
15984 |
| House: |
Commons |
| Date tabled: |
2024-11-25 |
| Asking Member ID: |
5219 |
| Asking Member display name: |
Mike Martin
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Mike Martin
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, if he will take steps to help negotiate an agreement between (a) AstraZeneca, (b) Daiichi Sankyo and (c) the National Institute for Health and Care Excellence to ensure Enhertu can be prescribed on |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2024-12-02 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Decisions on whether new medicines should be routinely funded by the National Health Service in England are made on the basis of recommendations from the National Institute for Health and Care Excellence (NICE), following an evaluation of a treatment’s co... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |